Download
1-s2.0-S1684118220300402-main.pdf 330,68KB
WeightNameValue
1000 Titel
  • Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths
1000 Autor/in
  1. Lai, Chih-Cheng |
  2. Liu, Yen Hung |
  3. Wang, Cheng-Yi |
  4. Wang, Ya-Hui |
  5. Hsueh, Shun-Chung |
  6. Yen, Muh-Yen |
  7. Ko, Wen-Chien |
  8. Hsueh, Po-Ren |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-04
1000 Erschienen in
1000 Quellenangabe
  • 53(3):404-412
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.jmii.2020.02.012 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128959/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most COVID-19 cases and mortalities were reported in China, the WHO has declared this outbreak as the sixth public health emergency of international concern. The COVID-19 can present as an asymptomatic carrier state, acute respiratory disease, and pneumonia. Adults represent the population with the highest infection rate; however, neonates, children, and elderly patients can also be infected by SARS-CoV-2. In addition, nosocomial infection of hospitalized patients and healthcare workers, and viral transmission from asymptomatic carriers are possible. The most common finding on chest imaging among patients with pneumonia was ground-glass opacity with bilateral involvement. Severe cases are more likely to be older patients with underlying comorbidities compared to mild cases. Indeed, age and disease severity may be correlated with the outcomes of COVID-19. To date, effective treatment is lacking; however, clinical trials investigating the efficacy of several agents, including remdesivir and chloroquine, are underway in China. Currently, effective infection control intervention is the only way to prevent the spread of SARS-CoV-2.
1000 Sacherschließung
lokal SARS-CoV-2
gnd 1206347392 COVID-19
lokal Asymptomatic carrier
lokal Acute respiratory disease
lokal 2019-nCoV
lokal Coronavirus
lokal Wuhan pneumonia
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGFpLCBDaGloLUNoZW5nIA==|https://frl.publisso.de/adhoc/uri/TGl1LCBZZW4gSHVuZyA=|https://frl.publisso.de/adhoc/uri/V2FuZywgQ2hlbmctWWk=|https://frl.publisso.de/adhoc/uri/V2FuZywgWWEtSHVp|https://frl.publisso.de/adhoc/uri/SHN1ZWgsIFNodW4tQ2h1bmc=|https://frl.publisso.de/adhoc/uri/WWVuLCBNdWgtWWVu|https://frl.publisso.de/adhoc/uri/S28sIFdlbi1DaGllbg==|https://frl.publisso.de/adhoc/uri/SHN1ZWgsIFBvLVJlbg==
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6421356.rdf
1000 Erstellt am 2020-06-17T07:27:38.969+0200
1000 Erstellt von 21
1000 beschreibt frl:6421356
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet Mon Sep 20 15:56:29 CEST 2021
1000 Objekt bearb. Mon Sep 20 15:56:29 CEST 2021
1000 Vgl. frl:6421356
1000 Oai Id
  1. oai:frl.publisso.de:frl:6421356 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source